As previously discussed, numerous GWAS and extensive functional studies have contributed to the PNPLA3 p.I148M variant being well characterised as an effect modifier of NAFLD progression, and thus a potential therapeutic target. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.